Import from '@/components/mdx'

Can I Take Glycine with AOD-9604?

What AOD-9604 Actually Is (and Is Not)

AOD-9604 is a 16-amino-acid synthetic fragment of the C-terminal end of human growth hormone, specifically residues 176 through 191. It was originally developed by Metabolic Pharmaceuticals as an anti-obesity agent. Early animal studies showed it could stimulate lipolysis and inhibit lipogenesis without the IGF-1-raising or glucose-dysregulating effects of full-length growth hormone. A Phase IIb trial (NCT00310219) published in 2007 found that oral AOD-9604 at doses of 1 mg per day did not significantly outperform placebo for weight loss at 24 weeks in adults with obesity, which led the manufacturer to halt that development program.

Today, AOD-9604 is compounded by 503A pharmacies for individual patient use. It is most often prescribed as a subcutaneous injection at doses ranging from 250 mcg to 300 mcg daily, typically administered in a fasted state in the morning or 30 to 60 minutes before exercise. The FDA has not approved AOD-9604 for any indication. That absence of approval matters for women reading this: there is no FDA-reviewed prescribing label, no formal drug-interaction database entry, and no large-scale safety data in women across reproductive stages.

How AOD-9604 Works at the Receptor Level

AOD-9604 appears to bind to the beta-3 adrenergic receptor in adipose tissue, activating hormone-sensitive lipase and promoting fat breakdown. Unlike full-length GH, it does not bind the GH receptor in a way that substantially raises IGF-1, which means it is not expected to drive the insulin resistance associated with exogenous GH use. One 2001 preclinical study in obese rodents confirmed lipolytic activity without significant changes in fasting glucose or IGF-1.

Why Women Ask About This Peptide Specifically

Women with PCOS, perimenopause-related central adiposity, or postpartum metabolic shifts are often the ones seeking peptide-based fat-loss strategies when diet and exercise plateaus occur. Declining estrogen in the perimenopause transition accelerates visceral fat accumulation, and endogenous GH pulsatility declines with age in women. Both of these biological realities make the adipose-targeted mechanism of AOD-9604 conceptually appealing. Appealing, though, is not the same as proven in a female-specific controlled trial.

What Glycine Does and Why Women Take It

Glycine is the simplest amino acid and is conditionally essential during periods of high metabolic demand, including pregnancy and rapid tissue repair. Women supplement glycine for three main reasons: sleep quality improvement, collagen synthesis support (skin, joint, gut lining), and potential metabolic benefits.

Sleep and GH Secretion

A 2012 randomized crossover study in humans found that 3 g of glycine taken before bed reduced sleep-onset latency and improved subjective sleep quality, with participants reporting less fatigue the next morning. The mechanism appears to involve glycine lowering core body temperature via peripheral vasodilation, which is the same physiological cue that initiates sleep. This is directly relevant to AOD-9604 users because the largest natural pulse of GH secretion occurs during slow-wave sleep, typically 60 to 90 minutes after sleep onset.

Glycemic Effects of Glycine

Glycine has demonstrated insulin-sensitizing effects in small human trials, including improvements in post-meal glucose excursions. A 2015 study in women with PCOS found that glycine supplementation alongside inositol improved insulin sensitivity markers compared to inositol alone, though sample sizes were small. For women who are also using AOD-9604 partly for metabolic reasons, the direction of effect here is additive rather than opposing, but it also means blood glucose could drop lower than expected, particularly in women using metformin or insulin alongside either agent.

Collagen and Connective Tissue

Glycine makes up roughly one-third of the amino acids in collagen. Supplemental glycine at 5 g per day alongside vitamin C has been shown to increase collagen synthesis markers in an 8-week trial. Women in perimenopause and beyond lose collagen more rapidly due to declining estrogen, so this is a frequently cited rationale for glycine supplementation in that population.

The Interaction: Pharmacokinetic vs. Pharmacodynamic

This is the question that matters most clinically, and the honest answer requires separating two categories.

No Meaningful Pharmacokinetic Interaction Is Expected

Pharmacokinetic interaction means one substance changes how the other is absorbed, distributed, metabolized, or excreted. AOD-9604 is a peptide administered subcutaneously. It is degraded by endopeptidases in tissue and circulation, not by hepatic CYP450 enzymes. Glycine is a free amino acid absorbed via intestinal transporters (SLC6A9 and related glycine transporters) and metabolized primarily through the glycine cleavage system in the liver and mitochondria. These pathways do not overlap in a clinically meaningful way. No published pharmacokinetic interaction data exists between these two compounds because no human trial has examined them together.

Pharmacodynamic Overlap: Three Areas to Watch

The WomanRx clinical team has organized the pharmacodynamic overlap between AOD-9604 and glycine into three domains that women and their prescribers should monitor:

1. GH Pulse Timing

AOD-9604 may support the amplitude of GH secretory pulses. Glycine, by improving slow-wave sleep, may extend the duration of the nightly GH pulse that occurs during deep sleep. In theory, these effects could be additive, producing a larger or longer GH secretory event. Whether that translates to meaningfully greater fat loss or body composition change in women is unknown because no trial has tested it. The risk of excessive GH activity (fluid retention, carpal tunnel, glucose elevation) appears low given AOD-9604's receptor profile, but women who notice joint swelling, morning stiffness, or unusual thirst should report these symptoms to their prescriber.

2. Insulin Sensitivity and Glucose

Both AOD-9604 (by virtue of not raising IGF-1 and not impairing glucose disposal) and glycine (via direct insulin-sensitizing mechanisms) trend toward improved glucose handling. For most healthy women, this is a benefit rather than a risk. For women with type 1 diabetes, or women on sulfonylureas, the combined glucose-lowering effect could be clinically relevant. If you are using either agent alongside glucose-lowering medications, monitor fasting and post-meal glucose more frequently when starting the combination, and inform your prescribing clinician.

3. Sleep Architecture and Recovery

Glycine at 3 g taken 30 to 60 minutes before bed consistently improves sleep onset and slow-wave sleep duration across multiple small human studies. AOD-9604 is typically dosed in the morning or pre-workout specifically to avoid competing with the endogenous nocturnal GH pulse. Separating AOD-9604 to morning dosing and glycine to bedtime therefore aligns with both agents' optimal timing windows and minimizes any theoretical interference.

Dose-Separation Windows: Do You Need Them?

No formal dose-separation window has been established in published literature for this combination, because no human trial has studied it directly. Clinically, the conventional approach used by compounding-prescribing practitioners is to separate them by time of day rather than a strict hour window: AOD-9604 is given subcutaneously in the morning, fasted, or 30 minutes before exercise; glycine is taken orally at bedtime. This schedule is practical and aligns with each agent's established efficacy timing rather than being a response to a documented interaction risk.

If you are taking AOD-9604 at bedtime for any reason (some practitioners dose it in the evening), spacing it at least two hours from glycine is a reasonable precaution to avoid any theoretical competition for GH-pulse timing, though this remains speculative.

Women-Specific Considerations by Life Stage

Reproductive Years (Ages Roughly 18 to 40)

Women in their reproductive years have higher baseline GH pulsatility than age-matched men, and estrogen amplifies GH secretion during the follicular phase of the menstrual cycle. This means the pharmacodynamic effects of AOD-9604 may vary across your cycle. Anecdotal reports from women using peptides suggest more pronounced effects in the first half of the cycle (estrogen-dominant phase) compared to the luteal phase, though no published data confirms this.

Glycine at supplemental doses has a reasonable short-term safety record in non-pregnant women. The Natural Medicines database rates glycine as "likely safe" at dietary and supplemental doses in healthy adults, though high-dose long-term human data is limited.

PCOS

Women with PCOS have blunted GH pulsatility and often have insulin resistance, hyperandrogenism, and anovulation. Both AOD-9604 (via lipolysis and possible metabolic improvement) and glycine (via insulin sensitization) have at least theoretical benefit in this population. A small 2016 trial found that glycine-containing supplements improved hormonal and metabolic markers in women with PCOS, though AOD-9604 has not been studied in PCOS at all. If you have PCOS, make sure your prescribing provider knows you are combining these agents and is monitoring androgen levels and insulin markers alongside any fat-loss endpoint.

Perimenopause and Menopause

Declining estrogen in perimenopause drives a reduction in endogenous GH pulsatility, increased visceral adiposity, worsening sleep quality, accelerated collagen loss, and rising insulin resistance. This profile means glycine and AOD-9604 each address a different piece of the perimenopausal metabolic picture: glycine targets sleep and collagen, AOD-9604 targets adipose tissue lipolysis.

The Menopause Society (formerly NAMS) does not have a formal position on peptide therapy, and AOD-9604 is not mentioned in current menopause management guidelines. Women in perimenopause considering this combination should be under the care of a clinician who can also evaluate whether hormonal support (estradiol, progesterone) or other interventions are more evidence-based for their individual symptom picture.

Postpartum and Lactation

AOD-9604 should not be used while breastfeeding. No lactation transfer data exists for this peptide, and the biological plausibility of GH-related peptide fragments passing into breast milk is sufficient reason to avoid it until more data is available. Glycine from food sources is present in breast milk naturally, and dietary glycine is safe during lactation. High-dose supplemental glycine (above 3 g per day) has not been formally studied in lactating women, so supplemental use should be discussed with a clinician.

Pregnancy and Contraception: Critical Safety Information

AOD-9604 is contraindicated in pregnancy. No human safety data exists for this peptide in pregnant women, and animal studies involving GH-axis peptides raise sufficient concern about interference with fetal growth regulation that use during pregnancy is not acceptable. If you are trying to conceive, you should discuss a plan to discontinue AOD-9604 before conception with your prescribing provider.

AOD-9604 does not function as a contraceptive and does not reliably prevent pregnancy. Women of reproductive age who do not wish to become pregnant while using AOD-9604 should use reliable contraception, and should stop AOD-9604 immediately if a pregnancy test is positive.

Glycine from food is a normal part of pregnancy nutrition. Supplemental glycine at doses used for sleep (3 g per night) has not been studied in prospective human pregnancy trials. The FDA has not assigned a formal pregnancy category to glycine as a supplement. Until data exists, supplemental glycine above dietary levels should be discussed with your obstetric provider during pregnancy. The American College of Obstetricians and Gynecologists recommends caution with any supplement not specifically studied in pregnancy.

Who This Combination Is and Is Not Right For

More Likely to Be Appropriate

Women who may reasonably consider this combination under clinician supervision include those who are:

• Post-menopausal with confirmed adipose excess and poor sleep quality, using AOD-9604 under compounding prescription and seeking to support sleep and collagen alongside it
• Non-pregnant women in their reproductive years with PCOS, metabolic dysfunction, and a prescriber managing their full metabolic panel
• Perimenopausal women who have already addressed hormonal status and are using AOD-9604 as an adjunct to lifestyle intervention for visceral fat

Not Appropriate

This combination is not appropriate for:

• Pregnant women or women actively trying to conceive without a clearance plan from their provider
• Breastfeeding women (AOD-9604 specifically)
• Women with active type 1 diabetes or on insulin and sulfonylureas, without close glucose monitoring
• Women with a history of any GH-secreting tumor or IGF-1-related malignancy
• Women who have not had a comprehensive metabolic panel, thyroid panel, and reproductive hormone workup before starting either agent

What to Monitor If You Are Already Taking Both

If you are already combining AOD-9604 and glycine, the following monitoring approach is reasonable:

Baseline and every 3 months: fasting glucose, fasting insulin, HOMA-IR if accessible, body weight and waist circumference.

At baseline: fasting IGF-1 (to rule out pre-existing elevation before starting a GH-adjacent peptide), thyroid panel (TSH, free T4), and in women with PCOS, total and free testosterone, DHEA-S.

Ongoing symptom tracking: sleep quality using a validated diary or wearable, energy levels, any joint swelling or morning stiffness (flag to prescriber if present), and menstrual cycle regularity for premenopausal women (cycle disruption is a non-specific stress signal worth logging).

If glucose monitoring shows fasting glucose below 70 mg/dL or post-meal readings below 60 mg/dL, reduce or hold glycine and contact your prescriber before continuing AOD-9604.

The Evidence Gap: What Is Known, What Is Extrapolated

Women have been underrepresented in peptide research broadly, and AOD-9604 research specifically. The Phase II clinical trial data that does exist from Metabolic Pharmaceuticals included mixed-sex cohorts and was not powered or designed to detect sex-specific differences in response. The 2007 trial reporting 24-week outcomes enrolled both men and women but did not report results stratified by sex.

Glycine human data is more strong than AOD-9604 human data, but still predominantly drawn from mixed-sex or male-majority samples. The sleep study by Inagawa et al. That is most frequently cited enrolled both sexes, but sample sizes were small enough (n=11 per crossover arm) that female-specific conclusions cannot be drawn.

The bottom line on evidence: the interaction profile described in this article is based on mechanism, individual-compound data, and pharmacological reasoning. No human trial has tested the combination of glycine and AOD-9604 directly. Any clinician or supplement company claiming proven combination between these agents is extrapolating beyond existing data.

"We simply do not have prospective data on how AOD-9604 behaves in women across the menstrual cycle, and stacking it with sleep-active amino acids before we have that foundational sex-stratified data is getting ahead of the science," says Dr. Maya Okafor, MD, WomanRx medical reviewer and women's health clinician. "That does not mean it cannot be done thoughtfully, but it does mean the monitoring has to be consistent and the prescriber has to be engaged."

Practical Dosing and Timing Summary

For women using both agents under clinician guidance, the following schedule reflects current compounding practice and individual-compound timing data:

| Agent | Typical Dose | Timing | Route | |---|---|---|---| | AOD-9604 | 250 to 300 mcg | Morning, fasted, or 30 min pre-exercise | Subcutaneous injection | | Glycine | 3 g | 30 to 60 min before bed | Oral (powder or capsule) |

Separating these agents by time of day addresses the theoretical concern about GH-pulse overlap and aligns each agent with its best-studied efficacy window. No additional dose adjustment of either agent is required solely because of the combination, in the absence of adverse symptoms or abnormal glucose readings.

If you are using AOD-9604 in the evening (some providers prescribe it this way to coordinate with the natural nocturnal GH pulse), space it at least 90 minutes from glycine and monitor sleep quality carefully. If sleep worsens rather than improves, that is a signal worth reporting.